Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.42 |
| ▸ | STS | P08842 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935343 | 0.89 | KDM4E (0.41) | CYP19A1KDM4ESMN1; SMN2POLBRXFP1 | |
| SCHEMBL13240265 | 0.88 | KDM4E (0.36) | CYP19A1KDM4ESMN1; SMN2POLBRXFP1 | |
| SCHEMBL12944797 | 0.87 | WDR5 (0.43) | CYP19A1KDM4ESMN1; SMN2POLBRXFP1 | |
| SCHEMBL936648 | 0.86 | SCN9A (0.43) | CYP19A1KDM4ERXFP1MEN1KMT2A | |
| SCHEMBL935369 | 0.76 | CYP19A1 (0.51) | CYP19A1STSKDM4E | |
| SCHEMBL930411 | 0.72 | CYP19A1 (0.48) | CYP19A1STSPOLBMEN1KMT2A | |
| SCHEMBL12908865 | 0.72 | POLB (0.43) | CYP19A1CA2POLB | |
| SCHEMBL12908853 | 0.72 | CYP1A2 (0.39) | CA2POLBMEN1KMT2A | |
| SCHEMBL12908855 | 0.70 | HDAC1 (0.46) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL12908864 | 0.70 | POLB (0.43) | CYP19A1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-8470860-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2013-06-25 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX, LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| US-7763642-B2 | Phenyl-sulfamates as aromatase inhibitors | STERIX LTD. (GB) | 2010-07-27 | — | — | US | disclosed |
| EP-1753732-B1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | STERIX LIMITED (GB) | 2007-05-24 | — | — | US | disclosed |
| EP-1753732-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118560-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117855-A1 | Phenyl-sulfamates as aromatase inhibitors | CYP19A1, CYP17A1, CYP21A2 | CYP19A1 1/4885STS 9/4885KDM4E 378/4885 |
| US-20110021586-A1 | PHENYL-SULFAMATES AS AROMATASE INHIBITORS | CYP19A1, CYP17A1, CYP21A2 | CYP19A1 1/4885STS 9/4885KDM4E 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.